Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…Abstract Number: 2866 • 2019 ACR/ARP Annual Meeting
Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus
Background/Purpose: Cardiac manifestations of neonatal lupus (NL) have been associated with significant morbidity and mortality, however there has been minimal information on long-term outcomes of…Abstract Number: 2931 • 2018 ACR/ARHP Annual Meeting
Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects
Background/Purpose: Missing data due to drop-out and loss to follow-up is a common problem in SLE trials. The usual approaches for handling this issue include…Abstract Number: 1854 • 2018 ACR/ARHP Annual Meeting
SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects women of childbearing age. Low disease activity for 6 months prior to conception leads to the best outcomes;…Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…Abstract Number: 1052 • 2016 ACR/ARHP Annual Meeting
Longitudinal Patterns in SLE Response to Standard of Care Therapy: Implications for SLE Clinical Trial Design
Background/Purpose: Most clinical trials of new treatments for systemic lupus erythematosus (SLE) have shown weak discrimination between investigational agents and placebo when added to standard…Abstract Number: 2196 • 2015 ACR/ARHP Annual Meeting
Association Between Antiphospholipid Antibodies and All-Cause Mortality Among End Stage Renal Disease Patients with and without SLE
Background/Purpose: We investigated the association between the presence of antiphospholipid antibodies (aPL) and/or lupus anticoagulant (LAC) (aPL/LAC+) and all-cause mortality among end stage renal…Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…Abstract Number: 987 • 2015 ACR/ARHP Annual Meeting
Pre-Emptive Renal Transplantation Among End Stage Renal Disease Patients with and without SLE
Background/Purpose: Lack of evidence-based recommendations about pre-emptive renal transplantation in systemic lupus erythematosus (SLE) patients with end stage renal disease (ESRD) may be unnecessarily delaying…Abstract Number: 768 • 2015 ACR/ARHP Annual Meeting
The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians
Background/Purpose: Current SLE disease activity measures, such as SLEDAI and BILAG, can be challenging to score and interpret, making them impractical for use in…Abstract Number: 872 • 2014 ACR/ARHP Annual Meeting
Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia
Background/Purpose: Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFN-α, a critical element in…Abstract Number: 1808 • 2013 ACR/ARHP Annual Meeting
Impact Of Baseline Disease Severity and Treatments On Outcomes In Clinical Trials Of SLE: Results From The Soccit Program
Background/Purpose: The Lupus Foundation of America Collective Data Analysis Initiative was established to evaluate SLE clinical trial design, using data collected from multiple studies. To…Abstract Number: 765 • 2013 ACR/ARHP Annual Meeting
Angiogenic Factor Dysregulation and Risk Of Adverse Pregnancy Outcome In Lupus Pregnancies
Background/Purpose: Pregnant women with lupus and APL are at increased risk for adverse outcomes, particularly preeclampsia (PE), yet identification of those destined for complications remains…
Advanced Search Results
-
Title
---